This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
Appropriate interpretation of results together with a genetic counselor can help clinicians to provide guidance to patients regarding clinical risk and genetic causes of diseases. The assay detects single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes. The assay provides >20X average coverage at the targeted genomic regions of the tested genes.
88 CLINICALLY-RELEVANT GENES
PROSTATENOW is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
LYNCHNOW is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.
DIABETESNOW is a unique genetic panel that tests for 16 genes associated with MODY, syndromic, neonatal, and mitochondrial causes of monogenic diabetes. It also includes pan-ancestry type 1 and 2 diabetes polygenic risk scores (PRS) and the probability of type 1 diabetes (GenProb-T1D).
We're here to guide you through the process.
Part of 88 GENE PANEL includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.
